ReviewDrug design, development and therapy2016
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Review in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- JAK-STAT Signaling in Autoimmunity and Cancer.ImmunoTargets and therapy · 2025Review
- Successful Treatment of Erosive Lichen Planus With Tofacitinib: A Case Series and Review of the Literature.Clinical medicine insights. Case reports · 2024Review
- Drug-induced liver injury due to tofacitinib: a case report.Journal of medical case reports · 2023Article
- Microneedle Mediated Iontophoretic Delivery of Tofacitinib Citrate.Pharmaceutical research · 2023Article
- A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.The Journal of clinical and aesthetic dermatology · 2022Review
- Finding Gene Regulatory Networks in Psoriasis: Application of a Tree-Based Machine Learning Approach.Frontiers in immunology · 2022Article
- Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.Pediatric rheumatology online journal · 2019Article
- Tofacitinib: A New Oral Therapy for Psoriasis.Clinical drug investigation · 2018Review
- Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.Open access Macedonian journal of medical sciences · 2018Article
- Psoriasis: A STAT3-Centric View.International journal of molecular sciences · 2018Review
- Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.Journal of immunology research · 2018Article
- JAK inhibitors in dermatology: The promise of a new drug class.Journal of the American Academy of Dermatology · 2017Review
- Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.Psoriasis (Auckland, N.Z.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies. Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal transducers and activators of transcription (STAT) pathways. JAKs are intracellular second messengers that are crucial for transmitting extracellular cytokine signals to the cell. JAK inhibition interrupts intracellular signaling and can suppress immune cell activation and inflammation in T-cell-mediated disorders, such as psoriasis. Consequently, JAKs are the subject of intensive research activity, since they represent possible therapeutic targets. Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the "JAK inhibitors", which target JAKs. Recently, oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis in randomized clinical trials. In particular, a 10 mg bid dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly. Questions remain unresolved regarding the safety risk beyond the 5 mg bid dose. This review, assessing the available scientific literature, focuses on the profile of tofacitinib, as investigational compound in the treatment of plaque psoriasis. An overview of the efficacy and safety data from randomized clinical trials is provided. In addition, the authors highlight future potential applications of tofacitinib in other skin diseases, in particular alopecia areata and vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.